Evidence map›Paper›PMID 26151266›Full record

ArticleJAMA2015

Association of Cardiometabolic Multimorbidity With Mortality.

Emerging Risk Factors Collaboration, Emanuele Di Angelantonio, Stephen Kaptoge, David Wormser, Peter Willeit, Adam S Butterworth, Narinder Bansal, Linda M O'Keeffe, Pei Gao, Angela M Wood and 80 more

Erratum issued 4 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in JAMA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 595 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
595citing papers in PubMed, 1 pooled it
40.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05367063 phase4completedstarted 2022, after this paper: background citation

Canagliflozin Attenuates CMR-Quantified Myocardial Fibrosis in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Ran2022Enrolled45Registered outcomes3Posted comparisons0ConditionsCardiovascular Risk, Type 2 DiabetesArmsCanagliflozin 100mg or Sitagliptin 100mg
Open the trial in the graph
NCT05975528 phase4unknown statusstarted 2023, after this paper: background citation

Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes

Ran2023Enrolled92Registered outcomes14Posted comparisons0ConditionsCellular Senescence, Diabetes Mellitus, Sodium-Glucose Transporter 2 InhibitorsArmsGlimepiride, SGLT2 inhibitor
Open the trial in the graph
NCT02989077 unknown statusnot on this mapstarted 2017, after this paper: background citation

Risk Profiling for Patients With Isolated or Combined Coronary and Cerebral Ischemia, and Their Current Status of Risk Factors Control

Typeobservational_patient_registrySponsorEgyptian Cerebro-Cardio-Vascular AssociationRan2017 to 2018Enrolled3,000ConditionsIschemia, Myocardial, Risk Factor, Cardiovascular, Ischemia, Cerebral
NCT04739254 suspendednot on this mapstarted 2020, after this paper: background citation

Magnetocardiography Endocrine Registry

TypeobservationalSponsorGenetesis Inc.Ran2020 to 2030Enrolled250ConditionsEndocrine DisorderArmsCardioFlux
3 · Its place in the literature

Who cites it

595 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,076 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

535 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

90 authors at 20 institutions in 15 countries.

Emerging Risk Factors Collaboration
Emanuele Di AngelantonioUniversity of Cambridge, Cambridge, England.
Stephen KaptogeUniversity of Cambridge, Cambridge, England.
David WormserUniversity of Cambridge, Cambridge, England.
Peter WilleitUniversity of Cambridge, Cambridge, England.
Adam S ButterworthUniversity of Cambridge, Cambridge, England.
Narinder BansalUniversity of Cambridge, Cambridge, England.
Linda M O'KeeffeUniversity of Cambridge, Cambridge, England.
Pei GaoUniversity of Cambridge, Cambridge, England.
Angela M WoodUniversity of Cambridge, Cambridge, England.
Stephen BurgessUniversity of Cambridge, Cambridge, England.
Daniel F FreitagUniversity of Cambridge, Cambridge, England.
Lisa PennellsUniversity of Cambridge, Cambridge, England.
Sanne A PetersUniversity Medical Center Utrecht, Utrecht, the Netherlands.
Carole L HartUniversity of Glasgow, Glasgow, Scotland.
Lise Lund HåheimUniversity of Oslo, Oslo, Norway.
Richard F GillumHoward University College of Medicine, Washington, DC.
Børge G NordestgaardCopenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.
Bruce M PsatyUniversity of Washington, Seattle.
Bu B YeapUniversity of Western Australia, Perth.
Matthew W KnuimanUniversity of Western Australia, Perth.
Paul J NietertDepartment of Public Health Sciences, Medical University of South Carolina, Charleston.
Jussi KauhanenUniversity of Eastern Finland, Kuopio.
Jukka T SalonenMetabolic Analytical Services Inc, Helsinki, Finland.
Lewis H KullerUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Leon A SimonsUniversity of New South Wales, New South Wales, Australia.
Yvonne T van der SchouwUniversity Medical Center Utrecht, Utrecht, the Netherlands.
Elizabeth Barrett-ConnorUniversity of California-San Diego, La Jolla.
Randi SelmerNorwegian Institute of Public Health, Oslo, Norway.
Carlos J CrespoPortland State University, Portland, Oregon.
Beatriz RodriguezUniversity of Hawaii, Honolulu.
W M Monique VerschurenNational Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Veikko SalomaaNational Institute for Health and Welfare, Helsinki, Finland.
Kurt SvärdsuddUppsala University, Uppsala, Sweden.
Pim van der HarstUniversity Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Cecilia BjörkelundUniversity of Gothenburg, Gothenburg, Sweden.
Lars WilhelmsenUniversity of Gothenburg, Gothenburg, Sweden.
Robert B WallaceDepartment of Epidemiology, University of Iowa, Iowa City.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Philippe AmouyelInstitut Pasteur de Lille, Lille, France.
Elizabeth L M BarrBaker IDI Heart and Diabetes Institute, Victoria, Australia.
Hiroyasu IsoOsaka University, Suita, Japan.
Altan OnatIstanbul University, Istanbul, Turkey.
Maurizio TrevisanCity College of New York, New York, New York.
Ralph B D'AgostinoBoston University, Boston, Massachusetts.
Cyrus CooperUniversity of Southampton, Southampton, England32University of Oxford, Oxford, England.
Maryam KavousiErasmus Medical Center, Rotterdam, the Netherlands.
Lennart WelinLidköping Hospital, Lidköping, Sweden.
Ronan RousselINSERM, Centre de Recherche des Cordeliers, Paris, France36Université Paris Diderot, Paris, France37Diabétologie, AP-HP, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France.
Frank B HuHarvard School of Public Health, Boston, Massachusetts.
Shinichi SatoOsaka Medical Center for Health Science and Promotion/Chiba Prefectural Institute of Public Health, Suita, Japan.
Karina W DavidsonColumbia University Medical Center, New York, New York.
Barbara V HowardMedStar Health Research Institute, Hyattsville, Maryland.
Maarten J G LeeningErasmus Medical Center, Rotterdam, the Netherlands.
Maarten LeeningErasmus Medical Center, Rotterdam, the Netherlands.
Annika RosengrenSahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Marcus DörrUniversity Medicine Greifswald, Greifswald, Germany44DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.
Dorly J H DeegVrije Universiteit Medical Center, Amsterdam, the Netherlands.
Stefan KiechlMedical University Innsbruck, Innsbruck, Austria.
Coen D A StehouwerMaastricht University Medical Centre, Maastricht, the Netherlands.
Aulikki NissinenNational Institute for Health and Welfare, Helsinki, Finland.
Simona GiampaoliIstituto Superiore di Sanità, Rome, Italy.
Chiara DonfrancescoIstituto Superiore di Sanità, Rome, Italy.
Daan KromhoutWageningen University, Wageningen, the Netherlands.
Jackie F PriceCentre for Population Health Sciences, University of Edinburgh, Edinburgh, Scotland.
Annette PetersInstitute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany52German Research Center for Cardiovascular Research (DZHK eV), Partner-Site Munich, Munich, Germany.
Tom W MeadeLondon School of Hygiene and Tropical Medicine, London, England.
Edoardo CasigliaUniversity of Padova, Padova, Italy.
Debbie A LawlorUniversity of Bristol, Bristol, England.
John GallacherCardiff University, Cardiff, England.
Dorothea NagelKlinikum der Universität München LMU, München, Germany.
Oscar H FrancoErasmus Medical Center, Rotterdam, the Netherlands.
Gerd AssmannAssmann-Stiftung für Prävention, Munster, Germany.
Gilles R DagenaisInstitut Universitaire de Cardiologie et Pneumologie de Québec, Quebec, Canada.
J Wouter JukemaLeiden University Medical Center, Leiden, the Netherlands.
Johan SundströmUppsala University, Uppsala, Sweden.
Mark WoodwardUniversity of Sydney, Sydney, Australia.
Eric J BrunnerUniversity College London, London, England.
Kay-Tee KhawUniversity of Cambridge, Cambridge, England.
Nicholas J WarehamMedical Research Council Epidemiology Unit, Cambridge, England.
Eric A WhitselDepartment of Medicine, University of North Carolina, Chapel Hill65Department of Epidemiology, University of North Carolina, Chapel Hill.
Inger NjølstadUniversity of Tromsø, Tromsø, Norway.
Bo HedbladLund University, Lund, Sweden.
Sylvia Wassertheil-SmollerAlbert Einstein College of Medicine, New York, New York.
Gunnar EngströmLund University, Lund, Sweden.
Wayne D RosamondUniversity of North Carolina, Chapel Hill.
Elizabeth SelvinJohns Hopkins University, Baltimore, Maryland.
Naveed SattarUniversity of Glasgow, Glasgow, Scotland.
Simon G ThompsonUniversity of Cambridge, Cambridge, England.
John DaneshUniversity of Cambridge, Cambridge, England.
University of Cambridge · GBErasmus MC · NLUniversity of Gothenburg · SEFinnish Institute for Health and Welfare · FIIstituto Superiore di Sanità · ITLund University · SEThe University of Western Australia · AUUniversity Medical Center Utrecht · NLUniversity of Glasgow · GBUniversity of North Carolina at Chapel Hill · USUppsala University · SEAlbert Einstein College of Medicine · USBaker Heart and Diabetes Institute · AUCardiff University · GBChiba Prefectural Institute of Public Health · JPCity College of New York · USColumbia University Irving Medical Center · USGerman Cancer Research Center · DEHarvard University · USHelmholtz Zentrum München · DE

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR000062 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2012 to 2014
$9.4M
British Heart Foundation RG/08/014/24067British Heart Foundation SP/09/002European Research Council 268834Medical Research Council G0400491Medical Research Council G0401527Medical Research Council G0700463Medical Research Council G0701619Medical Research Council G0800270Medical Research Council G1000143Medical Research Council MC_PC_12028Medical Research Council MC_QA137853Medical Research Council MC_U106179471Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1Medical Research Council MC_UU_12015/1Medical Research Council MR/L003120/1NCATS NIH HHS UL1 TR000062NCATS NIH HHS UL1 TR001450NIEHS NIH HHS P30 ES005605Wellcome Trust
6 · The paper itself

Abstract

importanceThe prevalence of cardiometabolic multimorbidity is increasing.

objectiveTo estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND

participantsAge- and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689,300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128,843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499,808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES: A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURES: All-cause mortality and estimated reductions in life expectancy.

resultsIn participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCE: Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity.

Indexed as

Diabetes MellitusLife ExpectancyMortalityMyocardial InfarctionStrokeAdultAgedComorbidityFemaleHumansMaleMiddle AgedRisk Factors

Identifiers

PMID26151266
PMCPMC4664176
OpenAlexW1932640386

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.